ERBB3 and head and neck squamous cell carcinoma: The results of this phase II study show that dual inhibition of HER3 and EGFR by single-agent duligotuzumab demonstrated activity comparable, but not superior, to single-agent cetuximab in second or more line R/M SCCHN.